NaF-PET drives management of prostate cancer, registry data suggest

03/19/2014 | AuntMinnie.com (free registration)

Data from the National Oncologic PET Registry revealed that NaF-PET led to a change in treatment strategy in 77% of patients staged using the approach. Management was also changed in 52% of patients believed to have initial bone metastases and 71% of patients whose bone metastases are believed to be progressing. "These data reflect referring physicians' confidence (or overconfidence) in NaF-PET's value in stratifying risk and their willingness to make definitive plans immediately," the authors wrote in the Journal of Nuclear Medicine.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN